These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25830297)

  • 1. Optimizing tuberculosis case detection through a novel diagnostic device placement model: the case of Uganda.
    Pho MT; Deo S; Palamountain KM; Joloba ML; Bajunirwe F; Katamba A
    PLoS One; 2015; 10(4):e0122574. PubMed ID: 25830297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of a clinical diagnostic algorithm for management of ambulatory smear and Xpert MTB/Rif negative HIV infected patients with presumptive pulmonary TB in Uganda: a prospective study.
    Walusimbi S; Semitala F; Bwanga F; Haile M; De Costa A; Davis L; Joloba M; Hoffner S; Kamya M
    Pan Afr Med J; 2016; 23():154. PubMed ID: 27303572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.
    Shah M; Dowdy D; Joloba M; Ssengooba W; Manabe YC; Ellner J; Dorman SE
    AIDS; 2013 Nov; 27(18):2883-92. PubMed ID: 25119690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in children: a prospective, multi-centre evaluation.
    Reither K; Manyama C; Clowes P; Rachow A; Mapamba D; Steiner A; Ross A; Mfinanga E; Sasamalo M; Nsubuga M; Aloi F; Cirillo D; Jugheli L; Lwilla F
    J Infect; 2015 Apr; 70(4):392-9. PubMed ID: 25312863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost analysis of different diagnostic algorithms for pulmonary tuberculosis varying in placement of Xpert MTB/RIF.
    Chadha VK; Sebastian G; Kumar P
    Indian J Tuberc; 2016 Jan; 63(1):19-27. PubMed ID: 27235940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
    Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
    PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation Research to Inform the Use of Xpert MTB/RIF in Primary Health Care Facilities in High TB and HIV Settings in Resource Constrained Settings.
    Muyoyeta M; Moyo M; Kasese N; Ndhlovu M; Milimo D; Mwanza W; Kapata N; Schaap A; Godfrey Faussett P; Ayles H
    PLoS One; 2015; 10(6):e0126376. PubMed ID: 26030301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic.
    O'Grady J; Bates M; Chilukutu L; Mzyece J; Cheelo B; Chilufya M; Mukonda L; Mumba M; Tembo J; Chomba M; Kapata N; Maeurer M; Rachow A; Clowes P; Hoelscher M; Mwaba P; Zumla A
    Clin Infect Dis; 2012 Nov; 55(9):1171-8. PubMed ID: 22806590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing laboratory costs of smear/culture and Xpert
    Naidoo P; Dunbar R; du Toit E; van Niekerk M; Squire SB; Beyers N; Madan J
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1377-1385. PubMed ID: 27725051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.
    Durovni B; Saraceni V; van den Hof S; Trajman A; Cordeiro-Santos M; Cavalcante S; Menezes A; Cobelens F
    PLoS Med; 2014 Dec; 11(12):e1001766. PubMed ID: 25490549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.
    Schnippel K; Meyer-Rath G; Long L; MacLeod W; Sanne I; Stevens WS; Rosen S
    Trop Med Int Health; 2012 Sep; 17(9):1142-51. PubMed ID: 22686606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation.
    Pooran A; Theron G; Zijenah L; Chanda D; Clowes P; Mwenge L; Mutenherwa F; Lecesse P; Metcalfe J; Sohn H; Hoelscher M; Pym A; Peter J; Dowdy D; Dheda K
    Lancet Glob Health; 2019 Jun; 7(6):e798-e807. PubMed ID: 31097281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in distribution and use of tuberculosis diagnostic tests in Kenya: a cross-sectional survey.
    Oliwa JN; Maina J; Ayieko P; Gathara D; Kathure IA; Masini E; Van't Hoog AH; van Hensbroek MB; English M
    BMC Infect Dis; 2018 Jul; 18(1):328. PubMed ID: 30012092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness.
    Hsiang E; Little KM; Haguma P; Hanrahan CF; Katamba A; Cattamanchi A; Davis JL; Vassall A; Dowdy D
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1212-8. PubMed ID: 27510248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach.
    Langley I; Lin HH; Egwaga S; Doulla B; Ku CC; Murray M; Cohen T; Squire SB
    Lancet Glob Health; 2014 Oct; 2(10):e581-91. PubMed ID: 25304634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area.
    You JH; Lui G; Kam KM; Lee NL
    J Infect; 2015 Apr; 70(4):409-14. PubMed ID: 25573001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid molecular detection of pulmonary tuberculosis in HIV-infected patients in Santiago, Chile.
    Balcells ME; García P; Chanqueo L; Bahamondes L; Lasso M; Gallardo AM; Cifuentes L
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1349-53. PubMed ID: 22863872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis.
    Thompson RR; Nalugwa T; Oyuku D; Tucker A; Nantale M; Nakaweesa A; Musinguzi J; Reza TF; Zimmer AJ; Ferguson O; Turyahabwe S; Joloba M; Cattamanchi A; Katamba A; Dowdy DW; Sohn H
    Lancet Glob Health; 2023 Feb; 11(2):e278-e286. PubMed ID: 36669808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study.
    Najjingo I; Muttamba W; Kirenga BJ; Nalunjogi J; Bakesiima R; Olweny F; Lusiba P; Katamba A; Joloba M; Ssengooba W
    PLoS One; 2019; 14(5):e0216901. PubMed ID: 31091275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.
    Theron G; Zijenah L; Chanda D; Clowes P; Rachow A; Lesosky M; Bara W; Mungofa S; Pai M; Hoelscher M; Dowdy D; Pym A; Mwaba P; Mason P; Peter J; Dheda K;
    Lancet; 2014 Feb; 383(9915):424-35. PubMed ID: 24176144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.